Podcasts about tocilizumab

What if cancer treatment could be made more effective by going straight to the source? In this episode of All Talk Oncology, Kenny Perkins sits down with Dr. Jason Williams, a pioneering interventional radiologist who is reshaping the future of cancer care through tumor-directed immunotherapy.   Dr. Williams shares how his childhood experience with his grandmother's breast cancer shaped his path toward developing innovative treatments. Instead of administering immunotherapy through traditional systemic methods, he and his team inject directly into tumors, enhancing immune response and potentially reducing side effects.   Key points discussed:   The origin and evolution of immunotherapy: from 2011 to now Why Dr. Williams transitioned from oncology to interventional radiology Direct tumor injection vs. systemic immunotherapy—why it matters Risks and overlooked dangers of traditional biopsy procedures How immune-stimulating drugs like Tocilizumab reduce side effects Addressing insurance limitations and off-label treatments The surprising link between Tylenol and immunotherapy effectiveness Clinical trials, success rates, and future directions in cancer treatment Why patients must take charge of their own care Immortalize your voice by being an ALL TALK ONCOLOGY GUEST! Just fill-out this FORM.   SOCIAL MEDIA LINKS: All Talk Oncology: Instagram & Facebook JOIN OUR FREE COMMUNITY: Facebook Community WEBSITE: https://www.alltalkoncology.com

Listen in as Cristina Mussini, MD; Martin Witzenrath, MD, FERS; and Michele Bartoletti, MD, PhD, discuss treatment strategies for people who are immunocompromised with COVID-19 in the hospital setting, including: Antiviral therapy with remdesivirDexamethasone for patients with hematologic malignanciesConsiderations regarding other immunomodulators such as JAK inhibitors or IL-6 inhibitorsA detailed patient case to illustrate key takeaways Presenters:Michele Bartoletti, MD, PhD​Associate Professor of Infectious DiseasesDepartment of Biomedical SciencesHumanitas UniversityPieve Emanuele (MI), ItalyHead of Infectious Diseases UnitIRCCS Humanitas Research HospitalRozzano (MI), ItalyCristina Mussini, MD​Full Professor of Infectious DiseasesChief of the Department of Infectious DiseasesUniversity of Modena and Reggio EmiliaModena, ItalyMartin Witzenrath, MD, FERS Medical DirectorCharite Centrum 12Internal Medicine & DermatologyProfessor and Chair for Respiratory Medicine and Critical CareDepartment of Infectious Disease, Respiratory Medicine and Critical CareCharite Campus Mitte/Campus Virchow Klinikum/Campus Benamin FranklinCharite – University of BerlinBerlin, GermanyLink to full program:https://bit.ly/4fs7HcbDownloadable slides:https://bit.ly/3XP1fpJGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Stephen Cantrill, MD, FACEP; Rajesh T. Gandhi, MD; and Payal K. Patel, MD, MPH, FIDSA, discuss: Workup of COVID-19 in the emergency departmentMethods of COVID-19 risk stratification Treatment recommendations for people with severe COVID-19, including how to effectively use antiviral therapy, dexamethasone, and other immunomodulators[CC1] in this population A detailed patient case to illustrate key takeawaysPresenters:Stephen Cantrill, MD, FACEP​Associate Director and Medical Director (Retired) ​ Department of Emergency Medicine​ Denver Health Medical Center​ Associate Professor ​ Department of Emergency Medicine​ University of Colorado Health Sciences Center​ Denver, Colorado Rajesh T. Gandhi, MD​Massachusetts General Hospital​ Professor of Medicine​ Harvard Medical School​ Boston, Massachusetts Payal K. Patel, MD, MPH, FIDSA​Systemwide Director of Antimicrobial Stewardship​ Associate Professor, Division of Infectious Diseases​ Intermountain Health​ Salt Lake City, Utah Link to full program: https://bit.ly/4gu2gcUGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Stephen Cantrill, MD, FACEP; Rajesh T. Gandhi, MD; and Payal K. Patel, MD, MPH, FIDSA, discuss treatment strategies for people who have severe COVID-19, including: Antiviral therapy with remdesivir Dexamethasone and other systemic corticosteroids Immunomodulators, such as JAK inhibitors or IL-6 inhibitors Overviews of clinical trial data demonstrating how and when to use these therapiesPresenters:Stephen Cantrill, MD, FACEP​Associate Director and Medical Director (Retired) ​ Department of Emergency Medicine​ Denver Health Medical Center​ Associate Professor ​ Department of Emergency Medicine​ University of Colorado Health Sciences Center​ Denver, Colorado Rajesh T. Gandhi, MD​Massachusetts General Hospital​ Professor of Medicine​ Harvard Medical School​ Boston, Massachusetts Payal K. Patel, MD, MPH, FIDSA​Systemwide Director of Antimicrobial Stewardship​ Associate Professor, Division of Infectious Diseases​ Intermountain Health​ Salt Lake City, Utah Link to full program: https://bit.ly/4gu2gcUGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.    

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:Early results with teclistamab combined with anti-CD38 therapyReal-world data with teclistamab including its use after other BCMA-targeted therapiesTalquetamab as bridging therapy to BCMA-targeted CAR T-cell therapyEvaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapyPresenter:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematologic MalignanciesConsultant, Division of HematologyProfessor of MedicineChair, Myeloma, Amyloidosis and Dysproteinemia GroupResearch Chair, Division of HematologyAssociate Chair for Research, Department of MedicineMayo ClinicRochester, MinnesotaLink to full program:https://bit.ly/40bjFCZ

(Actualidad Médica 30) Buen día, hoy otro podcast de Actualidad Médica.   Hoy vamos a explorar dos enfermedades reumatológicas complejas que afectan los vasos sanguíneos: la arteritis de células gigantes (ACG) y la arteritis de Takayasu (AT). Estas enfermedades, aunque poco comunes, pueden tener un impacto significativo en la vida de quienes las padecen.ENLACE: https://bit.ly/actualidadmédica30Te invitamos a que participes en la sección de comentarios.¿Qué quieres escuchar? ¿Cuáles son tus temas de interés?Síguenos en www.reumatimes.com, donde podrás encontrar cubrimientos de congresos de reumatología y resúmenes de actualidad en la especialidad. Encuéntranos en YouTube como ReumaTimes Y Facebook como Reumatologia.Online o ReumaTimes, en Instagram como dr.sebastianherrera o ReumaTimes, y en X (antes Twitter) como @Reuma_Online_ o @ReumaTimes. Estamos también en TikTok como @Reuma_Times.Síguenos en www.reumatimes.comTambién puedes encontrarnos en: Twitter: https://twitter.com/Reuma_Online_ Facebook: https://www.facebook.com/reumatologiaonline/ Instagram: https://www.instagram.com/dr.sebastianherrera/ Spreaker: https://www.spreaker.com/user/11390404 Spotify: https://spoti.fi/3DILwLP

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on neutrophil extracellular traps in ST-Segment elevation myocardial infarction.

Peds derm discussions with Dr. Lisa Swanson! - Infant gut microbiota and risk for allergic disease - Maternal vitamin D and atopic dermatitis - Tocilizumab for H syndrome - Nadolol = or > propranolol for hemangiomas Lisa Swanson can be found at lisaswansonmd@gmail.com Want to donate to the cause? Do so here!Donate to the podcast: uofuhealth.org/dermasphereCheck out our video content on YouTube:www.youtube.com/@dermaspherepodcastand VuMedi!: www.vumedi.com/channel/dermasphere/The University of Utah's DermatologyECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -⁠ Connect with us!- Web: ⁠dermaspherepodcast.com/⁠ - X: @DermaspherePC- Instagram: dermaspherepodcast- Facebook: www.facebook.com/DermaspherePodcast/- Check out Luke and Michelle's other podcast,SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠Dermasphere has received an unrestricted educational grant from Incyte Corporation. Thanks, Incyte!Check out our friends at:- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)- ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learnmore dermatology!

Dr. Vanessa Quick joins Dr. Ernest Choy to discuss her recent article on the impact of qwTCZ cessation on GCA patients. Looking at relapse rates and key risk factors, this discussion highlights the need for improving access to care and treatment for GCA patients, including increasing disease awareness, faster referral to specialised care, better access to diagnostic tools, and a multidisciplinary approach to managing this condition.You can read this article [https://doi.org/10.1093/rheumatology/kead604] in Rheumatology.Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram. Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

Pomegranate [Case Report] is a Q&A style podcast developed by trainees, for trainees. In our debut episode, we hear about w a who man presented to the emergency department reporting sudden onset vision loss in his right eye lasting several hours. He was 68 year old with a history of type 2 diabetes mellitus. Three differential diagnoses being considered were optic neuropathy, vitreoretinal disease, or corneal oedema following from potential uveitis. In this podcast consultant ophthalmologist, Dr Sumu Simon, walks through an approach to this presentation and an exploratory therapy.GuestsDr Sumu Simon FRANZCO (Queen Elizabeth Hospital; Royal Adelaide Hospital) Dr Brandon Stretton (Royal Adelaide Hospital) Dr Stephen Bacchi (Lyell McEwin Hospital)ProductionProduced by Mic Cavazzini DPhil. Music licenced from Epidemic Sound includes ‘Rockin' for Decades' by Blue Texas and ‘Brighton Breakdown' by BDBs. Image created and copyrighted by RACP. Editorial feedback kindly provided by RACP physicians Aidan Tan and Fionnuala Fagan. Please visit the Pomegranate Health web page for a transcript and supporting references. Login to MyCPD to record listening and reading as a prefilled learning activity. Key Reference and learning points (spoiler alert)The Role of Tocilizumab in Glucocorticoid Resistant Giant Cell Arteritis: A Case Series and Literature Review [J Neuroophthalmol. 2023;43(1)] 1.      This case underscores the critical nature of timely diagnosis and aggressive treatment in conditions like giant cell arteritis (GCA), where delayed treatment can lead to irreversible complications such as vision loss. Thorough history taking and clinical acumen are still key elements in establishing a diagnosis of GCA.2.      The patient's initial response and subsequent decline in vision illustrate the need for ongoing monitoring and readiness to adapt the treatment approach. It also shows the necessity of close monitoring of inflammatory markers and clinical symptoms.3.      Amaurosis fugax warrants urgent referral to an ophthalmologist.4.      High index of suspicion for GCA and prompt referral of GCA suspects will ensure best outcome for patients.5.      Progressive visual loss and elevated inflammatory markers should alert the clinician to glucocorticoid-resistant GCA.6.      The effectiveness of tocilizumab in this case highlights its role as a valuable treatment option for refractory GCA, especially when traditional therapies are not sufficiently effective. Targeted biologic agents may open up new treatment approaches in the future particularly in patients with progressive visual loss despite administration of intravenous methylprednisolone. 7.      Managing complex cases like GCA often requires a collaborative approach involving rheumatologists, ophthalmologists, and other specialists to ensure comprehensive care and optimal outcomes.8.      There is often value in case reports to start the evidence cascade that is required to bring new, life altering treatments to the forefront. 

Welcome to the 31st episode in my drug name pronunciation series.  Today, we're talking about tocilizumab-aazg, Tyenne ®, and Actemra®.    In this episode, I divide all three drug names into syllables, talk about tocilizumab's suffix, tell you which syllables to emphasize, and share my sources. The written pronunciations can be helpful, so you can see them below and in the show notes on thepharmacistsvoice.com.   tocilizumab-aazg - TOE si LIZ ue mab A-A-Z-G (Say one letter at a time for “aazg.") Emphasize TOE and LIZ.  Emphasize LIZ the most.   Sources:  USP Dictionary Online and Fresenius Kabi Media Relations    Tyenne = Tye-EN  Emphasize EN Source:  Medication Guide for Tyenne   Actemra = AC-TEM-RA  No syllable is emphasized.   Source: Medication Guide for Actemra   Thank you for listening to episode 276 of The Pharmacist's Voice ® Podcast!   To read the FULL show notes, visit https://www.thepharmacistsvoice.com.  Click the Podcast tab, and select episode 276.   Subscribe to or follow The Pharmacist's Voice ® Podcast to get each new episode delivered to your podcast player and YouTube every time a new one comes out!     Apple Podcasts   https://apple.co/42yqXOG  Spotify  https://spoti.fi/3qAk3uY  Amazon/Audible  https://adbl.co/43tM45P YouTube https://bit.ly/43Rnrjt   Links from this episode The Ohio Pharmacist's Association https://www.ohiopharmacists.org  FDA Purple Book https://purplebooksearch.fda.gov/  Choosing a suffix:  https://www.fda.gov/files/drugs/published/Nonproprietary-Naming-of-Biological-Products-Guidance-for-Industry.pdf (see page 10) USP Dictionary Online (aka “USAN”)  **Subscription-based resource USP Dictionary's (USAN) pronunciation guide (Free resource on the American Medical Association's website) The Pharmacist's Voice ® Podcast Episode 274, pronunciation series episode 30 (citalopram and escitalopram) The Pharmacist's Voice ® Podcast Episode 272, pronunciation series episode 29 (losartan) The Pharmacist's Voice Podcast Episode 269, pronunciation series episode 28 (tirzepatide) The Pharmacist's Voice Podcast Episode 267, pronunciation series episode 27 (atorvastatin)  The Pharmacist's Voice Podcast Episode 265, pronunciation series episode 26 (omeprazole) The Pharmacist's Voice Podcast Episode 263, pronunciation series episode 25 (PDE-5 inhibitors) The Pharmacist's Voice Podcast Episode 259, pronunciation series episode 24 (ketorolac) The Pharmacist's Voice ® Podcast episode 254, pronunciation series episode 23 (Paxlovid) The Pharmacist's Voice ® Podcast episode 250, pronunciation series episode 22 (metformin/Glucophage) The Pharmacist's Voice Podcast ® episode 245, pronunciation series episode 21 (naltrexone/Vivitrol) The Pharmacist's Voice ® Podcast episode 240, pronunciation series episode 20 (levalbuterol) The Pharmacist's Voice ® Podcast episode 236, pronunciation series episode 19 (phentermine)  The Pharmacist's Voice ® Podcast episode 228, pronunciation series episode 18 (ezetimibe) The Pharmacist's Voice ® Podcast episode 219, pronunciation series episode 17 (semaglutide) The Pharmacist's Voice ® Podcast episode 215, pronunciation series episode 16 (mifepristone and misoprostol) The Pharmacist's Voice ® Podcast episode 211, pronunciation series episode 15 (Humira®) The Pharmacist's Voice ® Podcast episode 202, pronunciation series episode 14 (SMZ-TMP) The Pharmacist's Voice ® Podcast episode 198, pronunciation series episode 13 (carisoprodol) The Pharmacist's Voice ® Podcast episode 194, pronunciation series episode 12 (tianeptine) The Pharmacist's Voice ® Podcast episode 188, pronunciation series episode 11 (insulin icodec)  The Pharmacist's Voice ® Podcast episode 184, pronunciation series episode 10 (phenytoin and isotretinoin) The Pharmacist's Voice ® Podcast episode 180, pronunciation series episode 9 Apretude® (cabotegravir) The Pharmacist's Voice ® Podcast episode 177, pronunciation series episode 8 (metoprolol)  The Pharmacist's Voice ® Podcast episode 164, pronunciation series episode 7 (levetiracetam) The Pharmacist's Voice ® Podcast episode 159, pronunciation series episode 6 (talimogene laherparepvec or T-VEC)  The Pharmacist's Voice ® Podcast episode 155, pronunciation series episode 5 Trulicity® (dulaglutide)  The Pharmacist's Voice ® Podcast episode 148, pronunciation series episode 4 Besponsa® (inotuzumab ozogamicin) The Pharmacist's Voice ® Podcast episode 142, pronunciation series episode 3 Zolmitriptan and Zokinvy The Pharmacist's Voice ® Podcast episode 138, pronunciation series episode 2 Molnupiravir and Taltz The Pharmacist's Voice ® Podcast episode 134, pronunciation series episode 1 Eszopiclone and Qulipta

Host Marilyn N. Bulloch, PharmD, BCPS, FCCM, is joined by Joy Peterson, PharmD, BCPS, BCIDP, Neha Paranjape, MD, MPH, to discuss the article, "Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19," (Crit Care Med. March 2023 51(3):337-346) which delves into the comparative outcomes, mortality rates, and adverse effects of baricitinib and tocilizumab in severe COVID-19 cases. Dr. Peterson is a Clinical Pharmacy Specialist in infectious disease, and Dr. Paranjape is an Infectious Disease Specialist at Wellstar Health System in Marietta, Georgia.

Here is information on the latest US FDA approvals, the week of March 4 – March 8, 2024 ·         ChatGPT4 in medical writing and editing—visit learnAMAstyle.com ·       Nascentmc.com for medical writing assistance for your company. Visit nascentmc.com/podcast for full show notes   - **OTC Glucose Monitor**: The FDA has approved the Dexcom Stelo Glucose Biosensor System for over-the-counter sale, a first for a continuous glucose monitor. Designed for people aged 18 and older not using insulin, it helps manage diabetes with oral medications or monitors the impact of diet and exercise on blood sugar levels. Scheduled for release in Summer 2024, the system offers a 15-day sensor wear time and does not alert users to low blood sugar episodes.   - **Semaglutide in CVD Risk**: The FDA has approved semaglutide (Wegovy) for reducing cardiovascular risk in adults with known heart disease who are overweight or obese, specifically targeting the reduction of major adverse cardiovascular events. This approval makes semaglutide the first weight-loss medication also indicated for preventing life-threatening cardiovascular events in patients with established cardiovascular disease and obesity or overweight.   - **Juvederm Additional Indication**: JUVÉDERM® VOLUMA® XC, a hyaluronic acid dermal filler, has received FDA approval for treating moderate to severe temple hollowing in adults over 21, marking it as the first HA filler for this purpose. With effects lasting up to 13 months, clinical studies show significant improvement and patient satisfaction with facial symmetry post-treatment. This approval highlights Allergan Aesthetics' commitment to innovation in aesthetic treatments.   - **Nivolumab in mUC**: The FDA approved nivolumab in combination with cisplatin and gemcitabine for first-line treatment of metastatic urothelial carcinoma, based on significant improvements in survival outcomes from the CHECKMATE-901 trial. This expands nivolumab's indications, which include treatments for melanoma and lung cancer, among others, demonstrating its broad applicability in cancer treatment.   - **Zanubrutinib in FL**: The FDA has granted accelerated approval to zanubrutinib and obinutuzumab for relapsed or refractory follicular lymphoma patients after two or more systemic therapies. This combination targets key pathways in B cell survival, offering a new treatment option for patients. Approval was based on the ROSEWOOD trial, highlighting significant patient outcome improvements.   - **Donanemab and Alzheimer's**: The FDA has postponed the decision on the approval of Eli Lilly's donanemab for Alzheimer's treatment to convene an advisory meeting for further examination of safety and efficacy data, indicating a significant delay. This reflects the complex nature of Alzheimer's drug approval and Eli Lilly's confidence in donanemab's potential benefits.   - **Tocilizumab Biosimilar**: Tyenne® (tocilizumab-aazg), the first FDA-approved biosimilar to Actemra® for various inflammatory diseases, is now available in both IV and subcutaneous formulations. This approval introduces a new treatment option for patients with conditions like rheumatoid arthritis and juvenile idiopathic arthritis, emphasizing advancements in biosimilar medications.   - **Denosumab Biosimilars**: The FDA approved Jubbonti and Wyost as interchangeable biosimilars to Prolia and Xgeva, respectively, marking a first for biosimilars targeting the RANKL inhibitor used in osteoporosis and cancer-related bone conditions. These approvals offer new treatment options for managing bone health, underlining the importance of biosimilar development in expanding patient care.   - **Clobetasol Propionate Eye Drops**: The FDA's approval of clobetasol propionate 0.05% eye drops for post-operative eye inflammation and pain introduces the first ophthalmic formulation of this corticosteroid and the first new steroid in ophthalmology in over 15 years. Developed using proprietary nanoparticle technology for twice-daily dosing, this approval offers a new option for effective pain and inflammation management post-eye surgery.

El Dr. Miguel Mesa nos trae la ReumaGuardia con el cubrimiento de las publicaciones más relevantes de la reumatología en junio de 2023.

In this episode, Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI, discusses new data on COVID-19 presented at ECCMID 2023, including:Treatment in special populationsREDPINE: remdesivir in people with renal impairment hospitalized for COVID-19 pneumoniaRemdesivir and readmission for COVID-19 in immunocompromised patientsMolnupiravir vs nirmatrelvir plus ritonavir for COVID-19 with hematologic malignancyManagement of patients with severe diseaseRECOVERY: higher-dose vs standard-dose corticosteroids for hospitalized patients with COVID-19Real-world study of tocilizumab vs baricitinib for severe COVID-19Novel antiviralsEnsitrelvirBemnifosbuvir Novel vaccinesNB2155AZD2816/AZD1222qNIV/CoV2373GRT-R910NVX-CoV2373 in people with HIVFaculty:  Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPIProfessor of Microbial DiseasesCentre for Experimental Pathogen Host ResearchUniversity College DublinDublin, IrelandContent based on an online CME/CE program supported by independent educational grants from Gilead Sciences, Inc. and Novavax.  Link to full program: bit.ly/3niXGJ6Link to downloadable slides: bit.ly/3LUFejG

Episodio 1 de ReumaGuardiaReferencias https://www.the-rheumatologist.org/issue/march-2023/vacunación articulo rheumatologist https://www.the-rheumatologist.org/article/acr-releases-new-vaccination-guideline/ Resumen 2023 rheumatologist https://www.the-rheumatologist.org/article/clinical-rheumatology-year-in-review-2022/ alerta denosumab rheumatologisthttps://www.the-rheumatologist.org/article/patients-on-dialysis-taking-denosumab-may-be-at-risk-of-severe-hypocalcemia/ Revisión entesitis Arthritis and rheumatologyhttps://onlinelibrary.wiley.com/toc/23265205/2023/75/4Editorial tocilizumabhttps://onlinelibrary.wiley.com/doi/10.1002/art.42299 https://onlinelibrary.wiley.com/doi/10.1002/art.42414 Diagnóstico pirofosfato de calcio https://onlinelibrary.wiley.com/doi/10.1002/art.42368 Nefritis lúpica ciudad de Nueva York https://onlinelibrary.wiley.com/doi/10.1002/art.42375 Tocilizumab en ACG efecto hemoglobina glicada https://onlinelibrary.wiley.com/doi/10.1002/art.42405 https://onlinelibrary.wiley.com/toc/25785745/2023/5/3ACR open https://onlinelibrary.wiley.com/doi/10.1002/acr2.11518Osteoartrosis y obesidad y síndrome metabólico hombre y mujer Cambios cognitivos en pacientes con lupus https://onlinelibrary.wiley.com/doi/10.1002/acr2.11529 Efecto multidominio guselkumab https://onlinelibrary.wiley.com/doi/10.1002/acr2.11523 https://rmdopen.bmj.com/SAF triple positivo perfil https://rmdopen.bmj.com/content/9/1/e002534 Cohorte francesa caracterización de pacientes con SAFhttps://rmdopen.bmj.com/content/9/1/e002881 Annals of rheumatic disease https://ard.bmj.com/content/82/4?current-issue=y vacunación y secuelas postagudas de covid https://ard.bmj.com/content/82/4/565 Progresión radiográfica de pacientes con espondilo, factores de riesgo genético https://ard.bmj.com/content/82/4/527 Factores de riesgo uso prolongado de esteroides en terapia puente https://ard.bmj.com/content/82/4/468 Esclerosis sistémica sin esclerodermiahttps://rmdopen.bmj.com/content/9/1/e002890.long

In this episode, Vikramjit Mukherjee, MD, and Cameron Smith, MPAS, PA-C, answer audience questions on how best to care for hospitalized patients with COVID-19 from a live, virtual question and answer webinar. This episode includes expert insights on:Supportive care management such as oxygen support, glycemic control, and anticoagulationEscalation of therapy in patients with worsening oxygen requirementsUse of remdesivir in patients with renal dysfunctionBrief commentary on long COVIDPresenters:Vikramjit Mukherjee, MDAssistant Professor  Division of Pulmonary, Critical Care, & Sleep Medicine  New York University School of Medicine  DirectorMedical Intensive Care UnitBellevue HospitalNew YorkCameron Smith MPAS, PA-CLead Advanced Practice ProviderMedical Intensive Care UnitBellevue HospitalNew York Health and Hospitals  New York, New YorkContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc.bit.ly/3z52c00

Dr. Ebell and Dr. Wilkes discuss the POEM titled ' Tocilizumab beneficial for adults with persistent polymyalgia rheumatica symptoms who receive steroid therapy '

In this episode, Princy N. Kumar, MD, and Paul E. Sax, MD, discuss new COVID-19 data from IDWeek 2022, including:COVID-19 vaccines, including omicron BA.1 bivalent boosterRisk factors for breakthrough COVID-19 infectionsCOVID-19 diagnostics, including digital droplet PCRCOVID-19 therapeutics, including:Nirmatrelvir plus ritonavirTixagevimab plus cilgavimabBaricitinibTocilizumabInhaled interferon β-1aCOVID-19 therapeutics and outcomes in patients with immunocompromiseLong COVIDPresenters:Princy N. Kumar, MD, FIDSA, MACPProfessor of Medicine and MicrobiologyChief, Division of Infectious Diseases and Travel MedicineSenior Associate Dean of StudentsGeorgetown University School of MedicineWashington, DCPaul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsFollow along with the downloadable slideset at:http://bit.ly/3gkJI67Link to full program:http://bit.ly/3TSVthM

In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Pakistan, polio by the numbers , influenza and COVID-19 vaccination coverage among health care personnel, phase 1/2a safety and immunogenicity of an adenovirus 26 vector RSV vaccine encoding prefusion F in adults 18–50 years and RSV seropositive children 12–24 months, receipt of first and second doses of JYNNEOS vaccine for prevention of Monkeypox, distinguishing SARS-CoV-2 persistence and reinfection, Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages, association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case, COVID-19 outcomes in solid organ transplant recipients who received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab treatment, Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralizing antibodies, and Tocilizumab versus Baricitinib in hospitalized patients with severe COVID-19. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Progress toward Poliomyelitis eradication (CDC) Polio by the numbers (JID) Influenza & COVID-19 vaccination coverage among health care personnel (CDC) Phase 1/2a Safety & Immunogenicity of an adenovirus RSV Vaccine (JID) Receipt of first & second doses of JYNNEOS vaccine  (CDC) Distinguishing SARS-CoV-2 persistence and reinfection (CID) Remdesivir fact sheet for providers (Veklury) Bebtelovimab fact sheet for providers (FDA) Novavax triggers potent neutralization of Omicron sub-lineages (bioRxiV) Association between physical activity & vaccination protective effect (BMJ) PAXLOVID patient eligibility screening checklist (FDA) COVID-19 outcomes in solid organ transplant recipients who received monoclonal antibodies (Transplantation) Omicron BA.2.75.2 exhibits escape from neutralizing antibodies (bioRxiV) Tocilizumab vs. Baricitinib in hospitalized patients with severe COVID-19 (CMI) Dr. Griffin's treatment guide (pdf) Contribute to Floating Doctors fundraiser at PWB Letters read on TWiV 949 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA, the Journal of the American Medical Association, for the September 20, 2022, issue.

This week's Stills disease Journal Club features expert discussants Drs. Olga Petryna, Daniel Lovell, Hermine Brunner and Jack Cush. Journal articles reviewed includes:  - CONSIDER Trial. Canakinumab for Treatment of Adult-Onset Still's Disease. Kedor C. Ann Rheum Dis 2020 Aug;79:1090-1097  https://bit.ly/3coPFg0 - TENDER Trial. Tocilizumab in systemic juvenile idiopathic arthritis. De Benedetti F. N Engl J Med. 2012 Dec 20;367:2385-95 https://bit.ly/3uXFq8Q

QD193 - Stills (or Not) MAS off of Tocilizumab   https://youtu.be/xIco2Xdxf68 QD194 - Stills (or Not) with Widespread Pain   https://youtu.be/50BXYafkVZM QD 195 - Stills (or Not) with Hives    https://youtu.be/f4tPMylrnpQ QD 196 - Stills (or Not); A Wifes Letter   https://youtu.be/eRnisH0Hjhw

Anti-inflammatory agents and immunomodulators are key components to treating patients who are severely or critically ill due to a COVID-19 infection.In this episode, Vikramjit Mukherjee, MD, discusses the role and timing of these treatment options, including:High-titer convalescent plasmaCorticosteroidsInterleukin-6 inhibitors (eg, tocilizumab)Janus kinase inhibitors (eg, baricitinib)Presenter:Vikramjit Mukherjee, MDAssistant Professor of MedicineDivision of Pulmonary, Critical Care, & Sleep MedicineNew York University School of MedicineDirector, Medical Intensive Care UnitBellevue HospitalNew York, New York Review the downloadable slidesets at: https://bit.ly/35NNb7QLink to full program: https://bit.ly/35SrxQ0

Pharma industry's Robinhood, Cipla is looking to increase its presence in the US market, the company's MD and Global CEO Umang Vohra. In this edition of The Medicine Box Podcast, CNBC-TV18's Ekta Batra talks to Vohra about Cipla's plan to capture a larger share of the US market, the firm's COVID-19 portfolio – from Tocilizumab to Remdesivir to Favipiravir, new products, growth outlook and more. Cipla, which is India's third largest pharma company and is present in more than 80 countries with over 46 manufacturing facilities, is looking to manufacture complex drugs and injectables in respiratory and cancer segments, Vohra said. Tune in to The Medicine Box Podcast for more 

Happy Father's Day to all the dads out there, and of course to Scott Morrison. The economy is bouncing back, what's going on with singles bubbles, and the most surprising of all - PVO got a prediction right!  In the latter part of the episode PVO mentions a drug used in the treatment of Covid. If you didn't get the spelling, it's Tocilizumab. See omnystudio.com/listener for privacy information.

Join Dr. Rahul Banerjee, Advanced Fellow of BMT / CAR T Therapy in the Department of Medicine at the University of California San Francisco, and Dr. Nina Shah, Associate Professor in the Department of Medicine at UC San Francisco, as they discuss their paper “Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.” The paper was co-authored by Drs. Shah and Banerjee, along with several colleagues, and was published in ASTCT's Transplantation and Cellular Therapy Journal in March.

Dr. Hareesh Singam, infectious diseases senior fellow at the University of South Florida College of Medicine, discusses some of the side effects associated with newer cancer therapies in this informative podcast. Dr. Singam broadly divides his remarks into two categories: Syndromes related to Immune Checkpoint Inhibitors, and Syndromes related to CAR-T Cell Therapy. He begins by briefly introducing the Immune Checkpoint Inhibitors (ICIs) and their mechanisms of action. He then discusses mechanisms of ICI toxicity and their clinical features. Dr. Singam goes on to discuss the associated infectious risks and how they are managed. Next, Dr Singham moves on to CAR-T Cell therapy, including its mechanisms of action, what occurs with cytokine release syndrome (CRS), and describes CAR-T Related Encephalopathy (CRES), CAR-T related hematophagic lyphohistiocytosis/macrophage activation syndrome (HLH/MAS), and the factors behind infectious risk after CAR-T therapy. Lastly, Dr. Singam discusses the use of Tocilizumab in CAR-T therapy.